These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

971 related articles for article (PubMed ID: 16916471)

  • 1. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
    Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
    BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation.
    Badier-Commander C; Verbeuren T; Lebard C; Michel JB; Jacob MP
    J Pathol; 2000 Sep; 192(1):105-12. PubMed ID: 10951407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
    Emenaker NJ; Basson MD
    J Surg Res; 1998 Apr; 76(1):41-6. PubMed ID: 9695737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
    Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
    Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
    Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
    Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
    Baker EA; Bergin FG; Leaper DJ
    Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melatonin inhibits postischemic matrix metalloproteinase-9 (MMP-9) activation via dual modulation of plasminogen/plasmin system and endogenous MMP inhibitor in mice subjected to transient focal cerebral ischemia.
    Tai SH; Chen HY; Lee EJ; Chen TY; Lin HW; Hung YC; Huang SY; Chen YH; Lee WT; Wu TS
    J Pineal Res; 2010 Nov; 49(4):332-41. PubMed ID: 20663046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.
    Nalbandian A; Djakiew D
    Clin Exp Metastasis; 2006; 23(2):107-16. PubMed ID: 16912916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
    Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
    Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
    Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
    Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and activation of proteases in co-cultures.
    Paduch R; Kandefer-Szerszeń M
    Exp Toxicol Pathol; 2011 Jan; 63(1-2):79-87. PubMed ID: 19836935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model.
    Deatrick KB; Eliason JL; Lynch EM; Moore AJ; Dewyer NA; Varma MR; Pearce CG; Upchurch GR; Wakefield TW; Henke PK
    J Vasc Surg; 2005 Jul; 42(1):140-8. PubMed ID: 16012463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
    Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
    J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain-derived neurotrophic factor inducing angiogenesis through modulation of matrix-degrading proteases.
    Sun CY; Hu Y; Wang HF; He WJ; Wang YD; Wu T
    Chin Med J (Engl); 2006 Apr; 119(7):589-95. PubMed ID: 16620701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
    Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
    Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue.
    González-Cuevas J; Bueno-Topete M; Armendariz-Borunda J
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1544-54. PubMed ID: 16928215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.